Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00033072
Status:
UNKNOWN
Last Update Posted:
2017-01-11
First Post:
2002-04-05
Brief Title:
Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline
Status:
UNKNOWN
Status Verified Date:
2003-11
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline
Detailed Description:
To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg 30mg iv with the focus being on cardiovascular responses HRBP to the iv methamphetamine challenges This is a randomized single-blind placebo-controlled two-arm study design to evaluate the safety of selegiline treatment compared to placebo treatment concurrent with iv methamphetamine challenges
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None